Efficacy of Topiramate in Adult Patients with Symptomatic Epilepsy: An Open-Label, Long-Term, Retrospective Observation

Yang Lu; Weihua Yu; Xuefeng Wang
April 2009
CNS Drugs;2009, Vol. 23 Issue 4, p351
Academic Journal
Background: Topiramate is a newer generation antiepileptic drug with a wide range of antiepileptic efficacy as monotherapy or as adjunctive therapy, and which has shown positive activity in intractable epilepsy and newly diagnosed epilepsy. Topiramate has also been shown to exert good seizure control with a low incidence of adverse effects in brain tumour-associated epilepsy. However, there have been few reports on the efficacy of topiramate in the treatment of symptomatic epilepsy of varying aetiologies. Objective: The aim of the present study was to evaluate the efficacy of topiramate in the treatment of adult patients with symptomatic epilepsy of various aetiologies. Methods: This was an open-label, long-term, retrospective observation. 227 patients with symptomatic epilepsy (110 male, 117 female) were enrolled into this study. The underlying aetiologies included low-grade brain tumour, head trauma, cerebrovascular diseases, infection, diabetes mellitus, hydrocephalus and parasitosis. Topiramate was titrated up to a target dosage of 200 mg/day and maintained for at least 1 year. Response to topiramate was defined as ≥50%reduction in seizure frequency compared with baseline. Seizure free was defined as no seizure occurring during 1 year of topiramate therapy. Results: 157 (69.2%) patients were responders and 124 (54.6%) patients were seizure free with topiramate administration. Responders by subgroup included 40 patients (74.0%) with low-grade brain tumour, 32 (55.2%) with trauma, 30 (90.9%) with cerebrovascular disease, 21 (55.3%) with infection, 18 (81.8%) with diabetes, 12 (85.7%) with parasitosis and 4 (50.0%) with hydrocephalus. The percentage of seizure-free patients by subgroup was 61.0% with brain tumours, 31.0%with trauma, 78.8%with cerebrovascular disease, 44.7%with infection, 59.0% with diabetes, 85.7% with parasitosis and 50.0% with hydrocephalus. The incidence of adverse effects was 36.1%. The most commonly reported adverse effects were weight loss, memory impairments, paraesthesia, headache and dizziness; most were mild to moderate in severity and transient. Sixty-eight (30.0%) patients withdrew from topiramate treatment in this study: topiramate was discontinued in 56 patients because of lack of efficacy and in 12 patients because of adverse effects. At the end of the study, 109 patients received topiramate monotherapy, including 52 newly diagnosed patients and 57 subjects who transferred to topiramate monotherapy successfully; another 118 patients received add-on topiramate therapy. The percentage of patients responding to topiramate was 85.3% in the monotherapy group and 54.2% in the topiramate add-on therapy group; the percentage of seizure-free patients was 68.8% in the topiramate monotherapy group and 41.5% in the topiramate add-on therapy group. Conclusion: When administered either as a single drug or as an add-on drug, topiramate is effective and well tolerated in adult patients with symptomatic epilepsy of various aetiologies.


Related Articles

  • When do epileptic patients need treatment? Starting and stopping medication. Chadwick, D.; Reynolds, E.H. // British Medical Journal (Clinical Research Edition);6/22/1985, Vol. 290 Issue 6485, p1885 

    Investigates the considerations in the antiepileptic treatments for patients with epilepsy. Administration of antiepileptic drugs prior to the occurrence of seizures; Adverse effects of antiepileptic drugs; Prognosis of epilepsy.

  • Topiramate audit study.  // Canadian Journal of Neurological Sciences;May2003 Supplement 2, Vol. 30, pS49 

    Presents an abstract of the study 'Topiramate Audit Study' submitted to the 38th meeting of the Canadian Congress of Neurological Sciences.

  • Duloxetine/topiramate.  // Reactions Weekly;Nov2014, Vol. 1527 Issue 1, p92 

    The article cites a study entitled "Topiramate and duloxetine induced myopic shift and bilateral closed-angled glaucoma," published in a previous issue of the journal.

  • Clinical Experience With Topiramate Dosing and Serum Levels in Children 12 Years or Under With Epilepsy. Schwabe, Michael J.; Wheless, James W. // Journal of Child Neurology;Nov2001, Vol. 16 Issue 11, p806 

    Only a limited topiramate dosing range (5-9 mg/kg/day) is approved by the U.S. Food and Drug Administration (FDA). We reviewed our topiramate dosing (mg/kg/d) and corresponding serum levels (µg/mL) (n = 77) in 41 children who were treated to clinical response or tolerability. The patients...

  • Phenytoin Overview--Metabolite Interference in Some Immunoassays Could Be Clinically Important. Soldin, Steven J.; Wang, Edward; Verjee, Zulfikarali; Elin, Ronald J. // Archives of Pathology & Laboratory Medicine;Dec2003, Vol. 127 Issue 12, p1623 

    Discusses the results of a study on phenytoin conducted by the College of American Pathologists. Significance of the discovery of phenytoin in the treatment of epilepsy; Phenytoin disposition; Toxic side effects of phenytoin; Methods of phenytoin measurement.

  • COMMENTARIES. Van de Winckel, Ann; Fonseca, Sergio T. // International Journal of Therapy & Rehabilitation;Oct2006, Vol. 13 Issue 10, p456 

    The article focuses on the quality of therapeutic programs aimed in improving the quality of movement and enhancing proprioception of during sensorimotor recovery in stroke patients. According to the author, the altered sensorimotor performance changes the individuals perception on its body and...

  • Poisoning with the New Anticonvulsant Drugs: Clinical Findings and the Outcome. Eizadi-Mood, Nastaran; Naderi, Hosnieh; Gheshlaghi, Farzad; Sabzghabaee, Ali Mohammad; Dana-Siadat, Zahra // Journal of Isfahan Medical School;8/22/2011, Vol. 29 Issue 144, p1 

    Background: Poisoning is one of the medical emergencies. Poisoning with new Anticonvulsant drugs such as lamotrigine, sodium valproate, topiramate and gabapentin has been observed alone or in combination with other drugs in the last few years. Therefore this study was performed regarding the...

  • Efficacy of topiramate (Topamax) in epileptic patients of different ages. K. Voronkova; O. Pylaeva; A. Petrukhin // Neuroscience & Behavioral Physiology;Jul2007, Vol. 37 Issue 6, p547 

    Abstract  The aim of the present work was to assess the efficacy and tolerance of topiramate (Topamax) in patients of different ages with different types of epilepsy. This agent was used as monotherapy and combined therapy in 114 patients (53 male, 61 female) of the following age groups:...

  • Topiramate.  // Reactions Weekly;9/6/2008, Issue 1218, p33 

    The article describes the case of a 35-year-old woman who developed palinopsia during topiramate treatment. She was presented for a psychiatric evaluation as part of an intended bariatric surgery. The patient had obesity, cyclothymic disorder, bulimia nervosa and borderline personality disorder....


Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics